Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.

Seongnam: SK bioscience, a global vaccine and biotech company, has announced that the Supreme Court of Korea has ruled in its ...

SK bioscience successfully developed Korea's first 13-valent pneumococcal conjugate vaccine, SKYPneumo, in 2016. However, due to the ongoing patent dispute with Pfizer, the company has been ...

South Korean vaccine company SK Bioscience said it has prevailed in a lawsuit brought by Pfizer that accused it of infringing on the patent for the drugmaker's Prevnar 13 vaccine.

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

The pneumococcal conjugate vaccine – codenamed PCV21/GBP410 – has started pivotal trials in the prevention of both paediatric Streptococcus pneumoniae, which remains a major public health ...

South Korean vaccine maker SK Bioscience has secured a final court victory over US pharma major Pfizer in a long-running ...

WHO, in collaboration with Somali federal and regional governments, to vaccinate 3.1M children under age of 5 during ...

The Supreme Court of Korea has ruled that the individual conjugates comprising SK Bioscience's 13-valent pneumococcal conjugate vaccine, or PCV13, don't fall within the scope of Pfizer's patent ...

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, ...

SK bioscience successfully developed Korea's first 13-valent pneumococcal conjugate vaccine, SKYPneumo, in 2016. However, due to the ongoing patent dispute with Pfizer, the company has been ...